MacroGenics

MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops new therapeutic product candidates using its antibody-based technology platforms and also in partnership with other biopharmaceutical companies. MacroGenics has a pipeline of product candidates in human clinical testing, primarily against various cancers. These include two product candidates developed using Fc Optimization platform, namely margetuximab, an antibody for the treatment of certain types of metastatic breast cancers and gastroesophageal cancers, and MGA271, an antibody to impact various tumors through multiple potential mechanisms of action. In addition, the Company has created different product candidates based on Dual-Affinity Re-Targetingr (DART) platform.

Type
Public
HQ
Rockville, US
Founded
2000
Size (employees)
318 (est)+19%
MacroGenics was founded in 2000 and is headquartered in Rockville, US

Key People at MacroGenics

Scott Koenig

Scott Koenig

President & Chief Executive Officer and Board Member
Ezio Bonvini

Ezio Bonvini

Senior Vice President, Research
Eric Risser

Eric Risser

Vice President, Development
James Karrels

James Karrels

Vice President, Chief Financial Officer
Lynn Cilinski

Lynn Cilinski

Vice President, Controller and Treasurer

MacroGenics Office Locations

MacroGenics has offices in Rockville and South San Francisco
Rockville, US (HQ)
9640 Medical Center Dr
Rockville, US
15235 Shady Grove Rd
South San Francisco, US
1 Corporate Dr

MacroGenics Data and Metrics

MacroGenics Financial Metrics

MacroGenics's revenue was reported to be $2.1 m in Q1, 2017
USD

Revenue (Q1, 2017)

2.1 m

Net income (Q1, 2017)

(37.7 m)

EBIT (Q1, 2017)

(38.2 m)

Market capitalization (25-Jul-2017)

611.1 m

Cash (31-Mar-2017)

40.5 m
MacroGenics's current market capitalization is $611.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

58 m47.8 m100.9 m91.9 m

Revenue growth, %

(18%)111%(9%)

R&D expense

122.1 m

General and administrative expense

29.8 m

Operating expense total

57.7 m86.1 m121 m151.9 m

EBIT

366 k(38.3 m)(20.2 m)(60 m)

EBIT margin, %

1%(80%)(20%)(65%)

Net Income

(260.8 k)(38.3 m)(20.1 m)(58.5 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

9.2 m18.4 m71.3 m6.7 m14.7 m2.8 m80.7 m3.3 m2.1 m

R&D expense

17.3 m18.6 m21.5 m22.7 m24.1 m27.3 m33.3 m30.3 m32.8 m

General and administrative expense

4.1 m3.7 m4.7 m5.3 m6 m6.1 m7.2 m7.2 m7.5 m

Operating expense total

21.5 m22.3 m26.1 m28 m30.1 m33.5 m40.6 m37.5 m40.3 m

EBIT

(12.3 m)(3.9 m)45.1 m(21.3 m)(15.4 m)(30.6 m)40.1 m(34.3 m)(38.2 m)

EBIT margin, %

(133%)(21%)63%(317%)(105%)(1076%)50%(1053%)(1859%)

Net Income

(15.4 m)(19.3 m)(30.4 m)10.1 m(23.7 m)(37.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

116.5 m157.6 m196.2 m84.1 m

Accounts Receivable

2 m2.9 m1.2 m2.8 m

Current Assets

119.5 m164.7 m342.4 m283.9 m

PP&E

5 m6.8 m14.8 m18 m

Total Assets

125.8 m173.9 m359.3 m311.3 m

Accounts Payable

3.2 m1.7 m3 m4 m

Current Liabilities

28.8 m27.1 m23.3 m27.3 m

Total Liabilities

42.5 m

Additional Paid-in Capital

254.5 m335.1 m547.2 m561.2 m

Retained Earnings

(175.7 m)(214 m)(234.2 m)(292.7 m)

Total Equity

78.9 m121.3 m313.3 m268.8 m

Financial Leverage

1.6 x1.4 x1.1 x1.2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

194 m179.2 m263.1 m235 m365.8 m152 m62.3 m109.9 m40.5 m

Accounts Receivable

2.6 m5.3 m1.7 m4.3 m2.7 m2.5 m78.4 m3 m2.1 m

Current Assets

198.8 m187 m268.5 m242.4 m370.5 m309.3 m348.4 m316.3 m251 m

PP&E

5.4 m5.6 m7.2 m9.4 m11.5 m14.3 m18.3 m18.5 m17.4 m

Total Assets

205.7 m193.6 m278.1 m254.2 m384.1 m325.7 m368.9 m339.9 m274.7 m

Accounts Payable

4 m4.4 m1.4 m1.9 m2.5 m1.1 m1.2 m1.4 m1.5 m

Current Liabilities

29.9 m26 m24.1 m23.8 m22.4 m17.8 m19.5 m22.1 m26.6 m

Additional Paid-in Capital

332.8 m333.8 m399.6 m401.7 m544.7 m550.4 m553.7 m557.7 m564.8 m

Retained Earnings

(191.1 m)(195 m)(168.9 m)(190.3 m)(205.7 m)(264.5 m)(224.1 m)(257.9 m)(330.4 m)

Total Equity

142 m139.1 m231 m211.7 m339.3 m286.3 m330 m300.1 m234.6 m

Financial Leverage

1.4 x1.4 x1.2 x1.2 x1.1 x1.1 x1.1 x1.1 x1.2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(260.8 k)(38.3 m)(20.1 m)(58.5 m)

Depreciation and Amortization

1.2 m1.8 m2.9 m7.6 m

Accounts Receivable

42.2 k(931 k)1.7 m(1.5 m)

Accounts Payable

(570.1 k)(1.5 m)(163 k)2.2 m

Cash From Operating Activities

(14.2 m)(32.8 m)(13.7 m)(43.7 m)

Purchases of PP&E

(3 m)(3.6 m)(9.2 m)(11.4 m)

Cash From Investing Activities

(3 m)(3.6 m)(152.1 m)(70.2 m)

Cash From Financing Activities

85.9 m77.4 m204.3 m1.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.4 m)(19.3 m)(30.4 m)10.1 m(23.7 m)(37.7 m)

Depreciation and Amortization

835 k1.3 m546 k1.2 m1.7 m1.8 m3.6 m5.6 m2 m

Accounts Receivable

(641 k)(3.3 m)1.2 m(1.4 m)191 k(1.3 m)(77.2 m)(1.8 m)671 k

Accounts Payable

808 k1.2 m(225 k)184 k872 k(388 k)(355 k)(133 k)(2.2 m)

Cash From Operating Activities

1.7 m(12.6 m)43.6 m18.1 m10.5 m(31.9 m)(65.1 m)(15.4 m)(35.3 m)

Purchases of PP&E

(1.2 m)(1.9 m)(997 k)(3.8 m)(6.4 m)(2.8 m)(8.3 m)(10.3 m)(1.5 m)

Cash From Investing Activities

(1.2 m)(1.9 m)(997 k)(3.8 m)(6.4 m)(12.5 m)(69.1 m)(72.3 m)(8.4 m)

Cash From Financing Activities

77 m77.2 m62.9 m63.1 m204.1 m224 k351 k1.4 m108 k
USDY, 2017

Revenue/Employee

6.5 k

Financial Leverage

1.2 x

MacroGenics Market Value History

MacroGenics Online and Social Media Presence

MacroGenics Company Life and Culture

You may also be interested in